Latest Healthcare Research Reports

Tag: companion diagnostics market research

  • 2024-2033 Companion Diagnostics Market Outlook: Unlocking Growth Potential

    2024-2033 Companion Diagnostics Market Outlook: Unlocking Growth Potential

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What is the Expected Growth Rate of the Companion Diagnostics Market from 2024 to 2033?

    The companion diagnostics market has grown exponentially in recent years. It is expected to rise from $6.26 billion in 2023 to $7.52 billion in 2024, reflecting a CAGR of 20.1%. This rapid growth is attributed to the increased adoption of personalized medicine, advancements in oncology and cancer therapies, pharmaceutical R&D collaborations, precision medicine, and biomarker discovery.

    The companion diagnostics market is set for exponential growth, reaching $15.8 billion by 2028, with a CAGR of 20.4%. This growth is fueled by targeted therapy development, rare disease diagnostics, and biomarker-based drug discovery. Key trends include AI in diagnostics, product innovations, and strategic collaborations.

    Claim Your Free Sample of the Global Companion Diagnostics Market Report Today!

    https://www.thebusinessresearchcompany.com/sample_request?id=7038&type=smp

    What Key Factors Are Fueling the Growth of the Companion Diagnostics Market?

    The rise in targeted therapies is boosting the companion diagnostics market. These therapies, which focus on specific cancer cell traits, are supported by companion diagnostic tests for personalized care. The European Society for Medical Oncology reported that genome-targeted therapy eligibility increased from 8.82% in previous years to 13.60% in 2020, emphasizing the market’s growth potential.

    What Are the Major Segments of the Companion Diagnostics Market?

    1) By Product And Service: Assays, Kits And Reagents, Software And Services

    2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

    3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

    4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

    What New Trends Are Transforming the Companion Diagnostics Market?

    Technological advancements in the companion diagnostics market are propelled by the use of artificial intelligence (AI) to develop more efficient drugs. For example, Deep Genomics, a Toronto-based startup, is using AI to identify better medications for genetic disorders. Through deep learning, AI enables scientists to test billions of chemical compounds to find potential treatments for diseases, accelerating the development of life-saving medicines.

    Order Now for Fast Delivery of Your Companion Diagnostics Market Report!

    https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

    Which Regions Are Driving Growth in the Companion Diagnostics Market?

    North America was the largest region in the companion diagnostics market in 2023. The regions covered in the companion diagnostics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    The Companion Diagnostics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the companion diagnostics market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Companion Diagnostics Market Include

    1. Companion Diagnostics Market Executive Summary

    2. Companion Diagnostics Market Segments

    3. Companion Diagnostics Market Size And Template Market Growth Rate

    4. Key Companion Diagnostics Market Trends

    5. Major Companion Diagnostics Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Companion Diagnostics Market

    26. Top Companion Diagnostics Companies

    27. Companion Diagnostics Market Opportunities And Strategies

    28. Companion Diagnostics Market, Conclusions And Recommendations

    29. Appendix

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

    Industry:

    Medical Equipment

    Meta Keywords:

    companion diagnostics market, companion diagnostics market size, companion diagnostics market share, global companion diagnostics market, companion diagnostics market growth, companion diagnostics market trends, companion diagnostics market overview, companion diagnostics market outlook, companion diagnostics market forecast, companion diagnostics market report, companion diagnostics market research

    The Business Research Company offers the companion diagnostics market research report 2024 with industry size, share, segments and market growth

    Global Companion Diagnostics Market, Global Companion Diagnostics Market Report, Global Companion Diagnostics Market Trends, Global Companion Diagnostics Market Size

  • Companion Diagnostics Market Size, Share, And Growth Rate Analysis 2023

    Companion Diagnostics Market Size, Share, And Growth Rate Analysis 2023

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

    The Business Research Company’s companion diagnostics market report forecasts the companion diagnostics market size to grow to $12.18 Billion by 2027, with a CAGR (compound annual growth rate) of more than 18%.

    Learn More On The Companion Diagnostics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

    Companion Diagnostics Market Size Forecast
    The global companion diagnostics market is expected to grow from $5.18 billion in 2022 to $6.16 billion in 2023 at a compound annual growth rate (CAGR) of 18.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The companion diagnostics market size is expected to grow to $12.18 billion in 2027 at a CAGR of 18.6%.

    North America held the largest companion diagnostics market share.

    Key Companion Diagnostics Market Driver ­– Increase In Number Of Targeted Therapies
    According to the April 2021 article of European Society for Medical Oncology, the genome-targeted therapy estimated eligibility was 8.82% by the end of 2018 and increase to 13.60% in 2020. Therefore, the rising number of therapies drives the companion diagnostics market.

    Request for A Sample Of The Global Companion Diagnostics Market Report:
    https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

    Key Companion Diagnostics Market Trend – Technological Advancement
    Artificial intelligence is used to develop more efficient drugs for companion diagnostics. The continuously gathered massive data sets from diverse genetic profiling have enabled the widespread application of AI. For instance, Deep Genomics, a Toronto-based start-up, is utilizing artificial intelligence to uncover better medications for genetic illnesses and speed up their introduction into clinical trials. The goal is to employ deep learning to explore the human genome for knowledge about the causes of diseases and to create and test chemical compounds that can be used as remedies. In a computer model, deep learning enables scientists to test billions of chemical compounds in search of promising formulations that they can turn into medicines that save lives for people worldwide.

    Companion Diagnostics Market Segment
    1) By Product And Service: Assays, Kits And Reagents, Software And Services
    2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry
    3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma
    4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

    Companion Diagnostics Market Major Players and Strategies
    Major players in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Myriad Genetics Inc., Almac Group, Illumina Inc., Seimens Healthineers AG, Abnova Corporation, Guardant Health Inc., ARUP Laboratories Inc., Foundation Medicine Inc., Bayer AG, Clinical Lab Products, Leica Biosystems Nussloch GmbH and Life Technologies Tm.

    In April 2021, Agilent Technologies Inc., a US-based Analytical laboratory company that manufactures instruments, reagents, software, services, and consumables for comprehensive laboratory workflow, acquired Resolution Bioscience for $695 million. With this acquisition, Agilent’s strengths in NGS-based cancer diagnostics are complements and expands, and also gives the company access to technology to meet the demands of the rapidly expanding precision medicine sector. Resolution Bioscience is a US-based healthcare research company specializing in NGS technology, molecular biology, cancer diagnostics, and more.

    The Companion Diagnostics Global Market Report 2023 covers regional data on companion diagnostics market size, companion diagnostics market trends and drivers, opportunities, strategies, and companion diagnostics market competitor analysis. The countries covered in the companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

    Companion diagnostics is an in vitro diagnostic medical test used to check the safety and effectivity of a corresponding drug or biological product. The test aids a medical expert to match a patient to a specific drug or therapy.

    View More Reports Related To The Companion Diagnostics Market –
    Cancer Diagnostics Global Market Report 2023
    Precision Medicine Global Market Report 2023
    Cervical Cancer Diagnostics Global Market Report 2023

    Contact us at:
    The Business Research Company: https://www.thebusinessresearchcompany.com/
    Americas     +1 3156230293
    Asia +44 2071930708
    Europe +44 2071930708
    Email us at info@tbrc.info

    Follow us on:
    LinkedIn: https://in.linkedin.com/company/the-business-research-company
    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
    Found this article helpful? Share it on:

  • How Is The Companion Diagnostics Market Expected To Grow Through 2024-2033

    How Is The Companion Diagnostics Market Expected To Grow Through 2024-2033

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    According to The Business Research Company’s Companion Diagnostics Global Market Report 2024, the companion diagnostics market is expected to show promising growth in the forecast period.

    The companion diagnostics market has witnessed remarkable growth in recent years, with a substantial surge from $6.26 billion in 2023 to $7.52 billion in 2024, showcasing a robust Compound Annual Growth Rate (CAGR) of 20.1%. The historic growth can be attributed to various factors such as increased adoption of personalized medicine, the expansion of oncology and cancer therapies, heightened collaboration in pharmaceutical R&D, precision medicine initiatives, and advancements in biomarker discovery.

    Anticipating the Future: Projected Expansion
    Forecasted Growth and Catalysts
    Looking ahead, the companion diagnostics market is poised for exponential growth, projected to reach $15.8 billion in 2028 with a CAGR of 20.4%. The forecasted expansion is fueled by factors including the development of targeted therapies, advancements in infectious disease diagnostics, increasing rare disease diagnostics, biomarker-based drug development, the rise of point-of-care testing, and applications of liquid biopsy. Major trends in the forecast period encompass immunotherapy and immunology advances, the integration of AI and machine learning in diagnostics, product innovations, the adoption of Industry 4.0, and strategic collaborations.

    Targeted Therapies Propelling Market Growth
    Understanding Targeted Therapies
    The exponential growth of the companion diagnostics market is closely tied to the increasing prevalence of targeted therapies. Targeted therapy, a pharmacological approach focusing on specific characteristics of cancer cells, inhibits the growth and spread of diseases. With fewer adverse effects compared to chemotherapy, biological marker-based companion diagnostics are becoming integral for personalized cancer care. The European Society for Medical Oncology reported an estimated eligibility increase from 8.82% in previous years to 13.60% in 2020 for genome-targeted therapy, highlighting the growing prominence of these therapies.

    • The increasing number of targeted therapies is a key driver for companion diagnostics market growth.
    • Genome-targeted therapy eligibility rose from 8.82% to 13.60% in 2020.

    Innovations Transforming Precision Medicine
    Innovative Treatment Solutions
    Major companies in the companion diagnostics market, including F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, and others, are at the forefront of developing groundbreaking solutions. The introduction of therascreen KRAS PCR Mutation Analysis exemplifies this innovation, offering a rapid and effective method to identify patients with non-small cell lung cancer. This companion diagnostic, launched by Laboratory Corporation of America Holdings, aids in identifying tumors with specific genetic mutations, ensuring patients receive the most effective and targeted treatments.

    • Innovative treatment solutions, like therascreen KRAS PCR Mutation Analysis, contribute to market growth.
    • The test aids in identifying patients with non-small cell lung cancer and specific genetic mutations.

    Strategic Moves: Acquisitions Driving Market Dynamics
    Agilent’s Acquisition of Resolution Bioscience
    In April 2021, Agilent Technologies Inc. acquired Resolution Bioscience for $695 million, strengthening its position in NGS-based cancer diagnostics. This strategic move enhances Agilent’s capabilities in precision medicine, aligning with the demands of the rapidly expanding sector. Resolution Bioscience, known for its expertise in NGS technology and molecular biology, brings valuable assets to Agilent’s portfolio.

    • Agilent Technologies’ acquisition of Resolution Bioscience enhances NGS-based cancer diagnostics capabilities.
    • The acquisition facilitates access to technology in the rapidly growing precision medicine sector.

    View More On The Companion Diagnostics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

    Market Segmentation: Understanding the Landscape
    Segmentation Overview
    The companion diagnostics market is segmented based on:

    1. Product And Service: Assays, Kits And Reagents, Software And Services
    2. Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry
    3. Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma
    4. End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations
    • Comprehensive segmentation provides insights into the diverse facets of the companion diagnostics market.

    Regional Dominance: North America Leading the Way
    North America’s Market Influence
    In 2023, North America emerged as the largest region in the companion diagnostics market, underscoring its significant role in shaping market dynamics and trends.

    • North America leads the companion diagnostics market, reflecting its influence in the sector.

    Conclusion: Embracing a Dynamic Future
    The companion diagnostics market is experiencing unparalleled growth, driven by factors such as the surge in targeted therapies, innovative treatment solutions, strategic acquisitions, and a robust focus on precision medicine. As the industry continues to evolve, staying attuned to emerging trends, technological advancements, and strategic collaborations will be essential for stakeholders looking to capitalize on the market’s exponential growth potential. The future of companion diagnostics promises transformative advancements, contributing to a more personalized and effective approach in the realm of diagnostics and therapeutics.

    Request A Sample Of The Global Companion Diagnostics Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=7038&type=smp